when continual immunosuppressive treatment was required. 1, 6,7 Unfortunately, administration of TMP/SMX can be associated with adverse effects, including myeloChildren who undergo bone marrow transplantation (BMT) are at risk for Pneumocystis carinii pneu-monia suppression, renal toxicity, skin rash, nausea and fever. [6][7][8] For patients undergoing BMT, myelosuppression is of (PCP).
For patients undergoing BMT, myelosuppression is of (PCP).
Prophylaxis using trimethoprim/sulfamethoxazole (TMP/SMX) is highly effective but the incimajor concern, especially if ganciclovir is required simultaneously. Renal dysfunction is problematic, particularly in dence of adverse drug reactions is significant. We retrospectively reviewed 33 pediatric BMT (25 allogeneic and patients already receiving potentially nephrotoxic drugs such as cyclosporine. Nausea, vomiting, and skin rash in eight autologous) in whom dapsone was used for PCP prophylaxis because patients were unable to receive the post-BMT period can be confused with acute graft-versus-host disease (GVHD).
TMP/SMX. Dapsone was administered at 50 mg/m 2 p.o. once a week from engraftment to 180 days post-autolog-
Oral dapsone has been used as an alternative to PCP prophylaxis in children with acquired immunodeficiency ous BMT, and to 1 year or throughout the duration of immunosuppressive treatment post-allogeneic BMT.
syndrome (AIDS) or cancer who are intolerant to TMP/SMX. 4, 5, 9 However, the use of dapsone prophylaxis With a total of 7268 patient days of dapsone prophylaxis and a median follow-up of 353 days post-BMT, no proin BMT recipients (children or adults) has not been reported previously. We report here our experience of using dapsone ven PCP was diagnosed. Sixteen cases of chest radiograph abnormalities were noted in this patient popufor PCP prophylaxis in pediatric BMT recipients who were intolerant or allergic to TMP/SMX. lation but none was attributed to PCP. Dapsone was well tolerated by all children with no serious adverse effects; however, one patient developed Toxoplasma gondii encephalitis during dapsone prophylaxis. Dapsone warrants further evaluation as an alternative for Materials and methods PCP prophylaxis in pediatric BMT patients intolerant of TMP/SMX. Additional prophylaxis should be considered for patients at high risk for T. gondii encepha-
The medical records of 96 consecutive children and adolescents who received BMTs at The University of Texas litis. Keywords: dapsone; Pneumocystis carinii; children; MD Anderson Cancer Center from July 1992 to October 1996 were reviewed. Patients were followed from the day bone marrow transplantation of admission for BMT to the most recent day of follow-up or death. The standard PCP prophylaxis regimen for BMT recipiWithout effective chemoprophylaxis, Pneumocystis carinii ents in our center is TMP/SMX (5 mg/kg/day twice a pneumonia (PCP) occurs in 5 to 15% of bone marrow transweek). Dapsone was used instead of TMP/SMX when (1) plant (BMT) recipients, and is associated with a mortality the patients had a history of allergy or were already on of approximately 60%. [1] [2] [3] Trimethoprim/sulfamethoxazole dapsone prior to BMT; (2) were intolerant of the standard (TMP/SMX) is effective for prevention of PCP in the regimen after BMT; or (3) their clinical condition such as immunocompromised host. 1, 4, 5 Over the last decade, the slow hematologic recovery or skin rash rendered the use of institution of TMP/SMX prophylaxis has almost completely TMP/SMX less desirable. Prophylactic dapsone was eliminated PCP in BMT recipients; documented infections administered at a dose of 50 mg/m 2 a week (rounded to were noted only after chemoprophylaxis had been interrupthe nearest 25 mg tablet) for 180 days to autologous BMT ted because of intolerance to the drug, noncompliance or recipients for 1 year to allogeneic BMT recipients or for as long as immunosuppressive treatment for GVHD was administered. P. carinii was routinely evaluated in lung
Results
to AP prophylaxis but none showed improvement of their liver function tests. No vomiting, diarrhea, skin rash, hemolysis or unexplained myelosuppression was temporally A total of 32 children underwent 33 (25 allogeneic and eight autologous) BMTs and received dapsone for PCP attributed to dapsone administration. Transfusion requirements were similar between patients receiving dapsone and prophylaxis (Table 1) . Patients were followed for a median of 349 days (range, 55 to 1245) post-BMT. The indications those on TMP/SMX (data not shown). One episode of Toxoplasma gondii encephalitis occurred 3 months postfor use of dapsone for PCP prevention were a history of allergic reaction to TMP/SMX (11 patients), concurrent BMT during dapsone prophylaxis in a patient from an endemic area. Dapsone prophylaxis was discontinued in 25 skin rash (six patients), nausea and vomiting (seven patients), slowly recovering blood counts (eight patients), cases: completion of prophylaxis schedule in 14 patients; death in five patients; hepatic GVHD in four patients and and intolerance to the taste of TMP/SMX (one patient). Dapsone was introduced at a median of 22 days (range, 11 change to TMP/SMX prophylaxis in two patients (including one patient with T. gondii encephalitis and one to 55) post-BMT and was administered for a median of 230 days (range, 14 to 667) in allogeneic BMT recipients and patient by the decision of his primary physician). Eight patients are still receiving dapsone at the time of this report. a median of 164 days (range, 47 to 275) in autologous BMT recipients. A total of 7268 patient-days of dapsone prophyNo PCP was diagnosed in the remaining 64 patients who received TMP/SMX prophylaxis post-BMT during the laxis were evaluated. Fourteen (56%) of the allogeneic BMTs were associated with grade II or greater acute same period of observation. GVHD and extensive chronic GHVD was diagnosed in nine (36%). Twenty-three (70%) of the patients received steroids for a median of 59 days (range, 5 to 518) for the Discussion treatment of GVHD, immune hemolytic anemia and recurrent leukemia.
Regular administration of TMP/SMX has been proven to be highly effective in the prevention of PCP in immunoNo episode of PCP or extrapulmonary P. carinii infection was diagnosed during the period of observation. There compromised patients. Unfortunately, 9-20% of children with leukemia have to discontinue TMP/SMX, mostly as were 16 episodes of chest radiographic abnormalities; in 10 episodes an infectious etiology other than PCP was diagthe result of myelosuppression or skin rash. 8, 10 The incidence of intolerance is even higher in children with AIDS, nosed by culture and/or response to antimicrobial therapy. Pulmonary hemorrhage was the cause in three other epiprobably as a result of the underlying disease and the number of drugs these patients are taking concomitantly. sodes. In the two remaining episodes, both BAL and autopsy showed no infectious etiology. In only one episode was Patients recovering after BMT are also often receiving multiple medications and battling with GVHD and opportunthe diagnosis uncertain (in a patient with hepatic GVHD and leukemia in relapse, whose family requested that no istic infections. When adverse reactions results in interruption of TMP/SMX prophylaxis post-transplant, PCP often invasive diagnostic or therapeutic interventions be performed). This patient had been switched to aerosolized develops. 7 An alternative to TMP/SMX for PCP prophylaxis is aerosolized pentamidine. The drawbacks of AP pentamidine (AP) prophylaxis 11 weeks earlier because of liver enzyme abnormalities. include a 5-9% incidence of bronchospasm, 10,11 absence of activity against T. gondii and extrapulmonary P. carinii Dapsone was well tolerated. Two children had prolonged anorexia and nausea. While on dapsone four patients infection, 5 and a significantly higher cost. From the current study, we found dapsone to be well developed GVHD involving the liver. They were switched tolerated in children intolerant or allergic to TMP/SMX. The once weekly schedule enhanced patient compliance. Despite the large number of medications these patients were receiving, we did not encounter any significant side-
effects related to dapsone. Our experience is similar to that of AIDS patients given low-dose dapsone, in whom only
Median age in years (range) 10 (1.5-21) mild and reversible effects were noted. 5,11-13 The observed safety of dapsone in our population may be secondary to BMT total 33 the dosage and schedule used. PCP prophylaxis is reported in AIDS patients. However, the optimal dosage and schedule has not been firmly estab- sive recovery of the immune system and the relative short
